Prevention of tuberculous cavity formation by immunosuppressive drugs.
D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000097:blood; D011817:Rabbits; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000473:pathology
D007166:Immunosuppressive Agents; D003609:Dactinomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001379:Azathioprine; D005472:Fluorouracil; D008727:Methotrexate